Created On: 2020-07-15
Record Count: 4
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2993
Through the License we are also a non-exclusive licensee of patents owned by the NIH related to the ability of our MVA vector vaccine to operate as a vehicle to deliver HIV virus antigens, and also to induce an immune response in humans.
IPSCIO Record ID: 275801
Licensed Product shall mean any HIV vaccine product other than the HIV Vaccine that cannot be developed, manufactured, used, or sold without infringing one or more Valid Claim under the Patent Rights.
The patents are titled: Polyvalent, Primary HIV -1 Envelope Glycoprotein DNA Vaccine, and, Polyvalent DNA and Protein Vaccines.
This technology is a DNA-based HIV vaccine that incorporates the 03-24 Technology and the 03-111 Technology. Invention disclosure number 03-24 is entitled Primary and Polyvalent IIlV-1 Envelope Glycoprotein DNA Vaccines. And HIV protein boost technology invention is referred to as 03-111.
New Vaccine shall mean any HIV vaccine other than the HIV Vaccine.
IPSCIO Record ID: 273729
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensee as UMMC 03-111.
IPSCIO Record ID: 27492